^
    CANCER:

    Mesothelioma





    Show legend
    Group by Gene:
    Include preclinical:

    nivolumab
    		0
    PD1 inhibitor
    pembrolizumab
    PD1 inhibitor
    PDR001
    gemcitabine
    		1
    DNA synthesis inhibitor
    cisplatin
    cisplatin + gemcitabine
    2
    PD1 inhibitor, CTLA4 inhibitor
    nivolumab + ipilimumab
    3
    Tubulin polymerization promoter
    carboplatin
    4
    Tubulin polymerization inhibitor
    vinorelbine tartrate
    5
    DNA synthesis inhibitor, Thymidylate synthase inhibitor
    cisplatin + raltitrexed
    6
    Tubulin polymerization promoter, Thymidylate synthase inhibitor
    carboplatin + raltitrexed
    7
    VEGFR-2 inhibitor
    ramucirumab
    8
    VEGF-A inhibitor
    bevacizumab
    9
    PARP inhibitor
    rucaparib
    olaparib
    10
    TEAD1 inhibitor
    IK-930
    SynKIR-110
    		11
    Mesothelin-targeted CAR-T immunotherapy
    MSLN-CAR-T cell therapy
    ATA3271
    12
    T-cell stimulant, Mesothelin inhibitor
    TC-210
    13
    PD1 inhibitor, PARP inhibitor
    niraparib + dostarlimab-gxly
    14
    PRMT5 inhibitor
    MRTX1719
    crizotinib
    		15
    ALK inhibitor
    ensartinib
    alectinib
    ceritinib
    16
    PD1 inhibitor, Multi-tyrosine kinase inhibitor
    pembrolizumab + nintedanib
    17
    EZH2 inhibitor
    tazemetostat
    18
    Wilms tumor 1 inhibitor, PD1 inhibitor
    nivolumab + galinpepimut-S
    19
    CDK4 inhibitor, CDK6 inhibitor
    abemaciclib
    20
    THF dehydrogenase inhibitor, Thymidylate synthase inhibitor
    pemetrexed
    21
    THF dehydrogenase inhibitor, Tubulin polymerization promoter, Thymidylate synthase inhibitor
    carboplatin + pemetrexed
    22
    PD-L1 inhibitor, VEGF-A inhibitor
    bevacizumab + atezolizumab
    23
    THF dehydrogenase inhibitor, DNA synthesis inhibitor, Thymidylate synthase inhibitor
    cisplatin + pemetrexed
    24
    Chemotherapy
    GC
    25
    FGFR inhibitor, EZH2 inhibitor
    FGFR inhibitor + EZH2 inhibitor
    26
    PD-L1 inhibitor
    PD-L1 inhibitor
    27
    ROS1 inhibitor, ALK inhibitor, Multi-tyrosine kinase inhibitor, FAK inhibitor
    APG-2449
    28
    THF dehydrogenase inhibitor, Arginine depleter, DNA synthesis inhibitor, Thymidylate synthase inhibitor
    cisplatin + pemetrexed + pegargiminase
    29
    PI3K inhibitor, mTOR inhibitor, ALK inhibitor, mTORC1 inhibitor, mTORC2 inhibitor
    ceritinib + PF-05212384
    30
    ALK inhibitor, EGFR inhibitor
    brigatinib
    31
    MEK1 inhibitor
    cobimetinib
    32
    Heat shock factor 1 inhibitor, NF-κB inhibitor, PI3K inhibitor, mTOR inhibitor, AKT inhibitor
    CBL0102
    33
    PLK1 inhibitor
    NBL-001
    34
    Aurora kinase A inhibitor
    MLN8237
    35
    Reactive oxygen species stimulant, Photosensitizer
    verteporfin
    36
    Bcl2 inhibitor, Bcl-xL inhibitor, Bcl-w inhibitor
    ABT 263
    37
    THF dehydrogenase inhibitor, Tubulin polymerization promoter, DNA synthesis inhibitor, Thymidylate synthase inhibitor
    cisplatin + carboplatin + pemetrexed + mitomycin
    38
    ROS1 inhibitor, ALK inhibitor
    lorlatinib
    39
    TEAD inhibitor
    TY-0584
    40
    DNA replication inhibitor, EGFR-targeted antibody-drug conjugate
    ABBV-321
    41
    ALK inhibitor, MEK1 inhibitor
    cobimetinib + ceritinib
    42
    MEK inhibitor
    trametinib
    No biomarker
    NF2 deletion
    BAP1 mutation
    BAP1 deletion
    MSLN positive
    MSLN expression
    MSLN overexpression
    BAP1 negative
    NF2 mutation
    PD-L1 overexpression
    BRCA1 mutation
    PD-L1 expression
    BRCA1 negative
    PD-L1 underexpression
    PD-1 overexpression
    ROS1 positive
    ERCC1 expression
    RRM1 expression
    ASS1 mutation
    CDKN2A negative
    WT1 expression
    MTAP deletion + CDKN2A deletion + CDKN2B deletion + BAP1 deletion
    MTAP deletion + PIK3CA mutation
    BRCA2 mutation
    ALK positive
    STRN-ALK rearrangement
    BAP1 negative + BRCA1 mutation
    MRE11A mutation
    TMB-L + BAP1 V99M + NF2 R34 + Chr del(14q) + Chr del(19q)
    CD74-ROS1 fusion
    STRN exon 2-ALK exon 20 fusion
    High 4-gene inflammatory score
    MSLN overexpression + PD-L1 overexpression
    KRAS mutation
    EGFR mutation
    TMB-L
    EGFR overexpression
    RB1 deletion
    LATS1 mutation
    LATS2 mutation
    EML4-ALK I1171N + EML4-ALK L1196M + EML4-ALK G1202R
    RASSF7 amplification
    EML4-ALK I1171N + EML4-ALK L1196M